Dysmyelinated Lower Motor Neurons Retract and Regenerate Dysfunctional Synaptic Terminals

Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.34). 05/2004; 24(15):3890-8. DOI: 10.1523/JNEUROSCI.4617-03.2004
Source: PubMed


Axonal degeneration is the major cause of permanent neurological disability in individuals with inherited diseases of myelin. Axonal and neuronal changes that precede axonal degeneration, however, are not well characterized. We show here that dysmyelinated lower motor neurons retract and regenerate dysfunctional presynaptic terminals, leading to severe neurological disability before axonal degeneration. In addition, dysmyelination led to a decreased synaptic quantal content, an indicator of synaptic dysfunction. The amplitude and rise time of miniature endplate potentials were also increased, but these changes were primarily consistent with an increase in the passive membrane properties of the transgenic muscle fibers. Maintenance of synaptic connections should be considered as a therapeutic target for slowing progression of neurological disability in primary diseases of myelin.

Download full-text


Available from: Erik P Pioro,
  • Source
    • "r junction of treated animals contribute to the clinical improvement in the mice and perhaps also to the increased num - bers of large - diameter axons in the treated nerves . Demyelinated axons have been shown to impair the regeneration of nerve ter - minals , resulting in dysfunctional presynaptic neuromuscular junc - tion following retraction ( Yin et al . , 2004 ) . At post - natal Day 13 when the neuromuscular junctions are still in a highly plastic phase ( Brill et al . , 2011 ) , the deficits are not yet pronounced , but they become gradually aggravated with ageing . Normally functioning neuromuscular junction are necessary to provide retrograde trans - port from muscle to the neuronal cell "
    [Show abstract] [Hide abstract]
    ABSTRACT: Charcot-Marie-Tooth disease type 1B is caused by mutations in myelin protein zero. R98C mice, an authentic model of early onset Charcot-Marie-Tooth disease type 1B, develop neuropathy in part because the misfolded mutant myelin protein zero is retained in the endoplasmic reticulum where it activates the unfolded protein response. Because oral curcumin, a component of the spice turmeric, has been shown to relieve endoplasmic reticulum stress and decrease the activation of the unfolded protein response, we treated R98C mutant mice with daily gastric lavage of curcumin or curcumin derivatives starting at 4 days of age and analysed them for clinical disability, electrophysiological parameters and peripheral nerve morphology. Heterozygous R98C mice treated with curcumin dissolved in sesame oil or phosphatidylcholine curcumin performed as well as wild-type littermates on a rotarod test and had increased numbers of large-diameter axons in their sciatic nerves. Treatment with the latter two compounds also increased compound muscle action potential amplitudes and the innervation of neuromuscular junctions in both heterozygous and homozygous R98C animals, but it did not improve nerve conduction velocity, myelin thickness, G-ratios or myelin period. The expression of c-Jun and suppressed cAMP-inducible POU (SCIP)-transcription factors that inhibit myelination when overexpressed-was also decreased by treatment. Consistent with its role in reducing endoplasmic reticulum stress, treatment with curcumin dissolved in sesame oil or phosphatidylcholine curcumin was associated with decreased X-box binding protein (XBP1) splicing. Taken together, these data demonstrate that treatment with curcumin dissolved in sesame oil or phosphatidylcholine curcumin improves the peripheral neuropathy of R98C mice by alleviating endoplasmic reticulum stress, by reducing the activation of unfolded protein response and by promoting Schwann cell differentiation.
    Brain 12/2012; 135(Pt 12):3551-66. DOI:10.1093/brain/aws299 · 9.20 Impact Factor
  • Source
    • "In addition, retraction of nerve terminals increased over ten-fold at PSC-ablated NMJs (Reddy et al., 2003). A similar dependence of axon terminal stability from MSCs has been observed in various dysmyelinating axon pathologies (Scherer, 1999; Martini, 2001; Yin et al., 2004). The analogous experiment to PSC ablation at the mammalian NMJ requires injection of a subset of anti-disialosyl antibodies to selectively remove TSCs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glia are an indispensable structural and functional component of the synapse. They modulate synaptic transmission and also play important roles in synapse formation and maintenance. The vertebrate neuromuscular junction (NMJ) is a classic model synapse. Due to its large size, simplicity and accessibility, the NMJ has contributed greatly to our understanding of synapse development and organization. In the past decade, the NMJ has also emerged as an effective model for studying glia-synapse interactions, in part due to the development of various labeling techniques that permit NMJs and associated Schwann cells (the glia at NMJs) to be visualized in vitro and in vivo. These approaches have demonstrated that Schwann cells are actively involved in synapse remodeling both during early development and in post-injury reinnervation. In vivo imaging has also recently been combined with serial section transmission electron microscopic (ssTEM) reconstruction to directly examine the ultrastructural organization of remodeling NMJs. In this review, we focus on the anatomical studies of Schwann cell dynamics and their roles in formation, maturation and remodeling of vertebrate NMJs using the highest temporal and spatial resolution methods currently available.
    Neuron Glia Biology 11/2009; 4(4):319-26. DOI:10.1017/S1740925X09990421 · 6.64 Impact Factor
  • Source
    • "When FAT stops, retrograde transport of neurotrophins also stops (Fig. 2). Neurotrophins signal the cell body that it is part of a functioning circuit, and their absence may cause neuron loss (Dorsey et al., 2006; Lazarov et al., 2007; Salehi et al., 2006) and permanent disability (Yin et al., 2004) (Fig. 3). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The amyloid hypothesis (AH) of Alzheimer's disease (AD) posits that the fundamental cause of AD is the accumulation of the peptide amyloid beta (Aβ) in the brain. This hypothesis has been supported by observations that genetic defects in amyloid precursor protein (APP) and presenilin increase Aβ production and cause familial AD (FAD). The AH is widely accepted but does not account for important phenomena including recent failures of clinical trials to impact dementia in humans even after successfully reducing Aβ deposits. Herein, the AH is viewed from the broader overarching perspective of the myelin model of the human brain that focuses on functioning brain circuits and encompasses white matter and myelin in addition to neurons and synapses. The model proposes that the recently evolved and extensive myelination of the human brain underlies both our unique abilities and susceptibility to highly prevalent age-related neuropsychiatric disorders such as late onset AD (LOAD). It regards oligodendrocytes and the myelin they produce as being both critical for circuit function and uniquely vulnerable to damage. This perspective reframes key observations such as axonal transport disruptions, formation of axonal swellings/sphenoids and neuritic plaques, and proteinaceous deposits such as Aβ and tau as by-products of homeostatic myelin repair processes. It delineates empirically testable mechanisms of action for genes underlying FAD and LOAD and provides "upstream" treatment targets. Such interventions could potentially treat multiple degenerative brain disorders by mitigating the effects of aging and associated changes in iron, cholesterol, and free radicals on oligodendrocytes and their myelin.
    Neurobiology of aging 09/2009; 32(8):1341-71. DOI:10.1016/j.neurobiolaging.2009.08.007 · 5.01 Impact Factor
Show more